

# Peritoneal Dialysis Prescription and Adequacy Monitoring

Annabelle N. Chua, MD

May 5, 2021

# *Disclosures*

No financial disclosures relevant to this talk

*Acknowledgment:*

Some slides previously borrowed/modified  
from Dr. Christine Sethna

# Overview

- Physiology of the peritoneal membrane
- Clinical factors that impact peritoneal dialysis (PD) prescription in the pediatric population
- Role of dialysis adequacy to monitor the effectiveness of peritoneal dialysis

# *Why Peritoneal Dialysis?*

## **Advantages**

- Vascular access not required
- Improved fluid balance; less antihypertensive medications
- Fewer dietary restrictions
- Relatively safe and simple
- Allows for regular school attendance
- Better growth
- Better for infants
- Less travel to dialysis unit

## **Disadvantages**

- Risk of infection (peritonitis, exit site and tunnel infections)
- Hernias
- Labor intensive; increased caregiver burden
  - Risk of non-adherence
- Decreased appetite
- Body image disturbance

# *Contraindications to PD*


## **ABSOLUTE**

- Omphalocele
- Gastroschisis
- Bladder Exstrophy
- Diaphragmatic hernia
- Obliterated peritoneal cavity
- Peritoneal membrane failure


## **RELATIVE**

- Impending abdominal surgery
- Impending (<6months) living-donor kidney transplantation
- Lack of appropriate caregiver for home therapy; lack of appropriate home environment

# PD Prescription



# Physiology of Peritoneal Membrane




# *PD Prescription Components*

- Modality – CAPD vs APD
- Solution
- Fill volume
- Dwell Time
- Number of Exchanges



# Modality – Continuous Ambulatory Peritoneal Dialysis (CAPD)



- Provides continuous solute and fluid removal throughout the day and night
- Daytime exchanges ~5 hours
- Nighttime exchange ~9 hours
- Ease of use
- Low cost of equipment
- Often used in developing countries with limited resources available


# Modality – Automated Peritoneal Dialysis (APD)




- Continuous Cycling (CCPD)
- Nightly Intermittent (NIPD)
- Tidal (TPD)



# Peritoneal dialysis formats



# Adapted APD



Water and  
small molecules

Sodium and  
large molecules  
(uremic toxins)

# *PD Rx: Modality*

## Determinants of Modality Choice

- Financial
- Center preference
- Geography
- Lifestyle
- Peritoneal membrane transport characteristics

# PD Rx: Solution


## Composition:

- Water
- Osmotic agent
  - Dextrose (1.5%, 2.5%, 4.25%)
  - Icodextrin
  - Amino acids
- Buffer
  - Lactate
  - Bicarbonate



- Electrolytes
  - Sodium 132-134 mEq/L
  - Chloride 96-105 mEq/L
  - Magnesium 0.25-0.5 mEq/L
  - Calcium 2-3.5 mEq/L
  - No potassium
- Additives
  - Heparin
  - Antibiotics

# PD Rx: Solution





# Solutions

**Table 1** | Selected peritoneal dialysis solutions currently available in Europe

Solution (manufacturer)	pH	Chambers	Buffer	Osmotic agent	GDPs	Advantages	Disadvantages
Dianeal® (Baxter*)	5.2	Single	Lactate	Glucose	High	Easy to manufacture; low cost	Low pH; poor peritoneal membrane biocompatibility; infusion pain; contains lactate
Extraneal® (Baxter*)	5.6	Single	Lactate	Icodextrin	Low	Sustained ultrafiltration; reduced nutrition	Contains lactate; low pH; single daily use only; hypersensitivity
Nutrineal® (Baxter*)	5.5	Single	Lactate	Amino acids	No		Contains lactate; low pH; single daily use only
Physioneal® (Baxter*)	7.4	Double	Lactate/bicarbonate	Glucose	Low	Improved biocompatibility; preserved membrane defense; reduced infusion pain	Local and systemic glucose exposure; reduced peritoneal lactate exposure
Stay-safe® (Fresenius†)	5.5	Single	Lactate	Glucose	High	Ease of manufacture; low cost	Low pH; poor peritoneal membrane biocompatibility; infusion pain; contains lactate
Balance® (Fresenius†)	7.0	Double	Lactate	Glucose	Low	Improved biocompatibility; preserved membrane defense; reduced risk of peritonitis?	Higher but not neutral pH; local and systemic glucose exposure; contains lactate
BicaVera® (Fresenius†)	7.4	Double	Bicarbonate	Glucose	Low	Improved biocompatibility; preserved membrane defense; improved correction of acidosis	Local and systemic glucose exposure
Gambrosol® Trio (Fresenius†)	6.5	Triple	Lactate	Glucose	Low	Improved biocompatibility; preserved membrane defense	Higher but not neutral pH; local and systemic glucose exposure; contains lactate


Glucose degradation products

Delflex


\*Deerfield, IL, USA. †Bad Homburg, Germany. Abbreviation: GDPs, glucose degradation products.



# Effects of Conventional Solutions



# Effects of Conventional Solutions



## Harmful systemic effects

- Fluid and sodium retention
- Left ventricular hypertrophy
- Hyperglycemia
- Hyperinsulinemia
- Hyperlipidemia
- Abdominal obesity


Suboptimal patient and technique survival

# Biocompatible Solutions


## Improved peritoneal membrane viability

- Attenuation of peritoneal fibrosis
- Preservation of peritoneal cell viability and function
- Less AGE accumulation
- Less inflammation

Normal peritoneal membrane



# Effects of Biocompatible Solutions



- Improved systemic effects
- Improved metabolic control
  - Improved body composition
  - Improved UF capacity
  - Improved fluid status
  - Preservation of RRF?
  - Reduced peritonitis rate?
  - Reduced systemic inflammation?

Improved patient and technique survival?

# PD Rx: Solution

## Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis

Il-Soo Ha<sup>1</sup>, Hui K. Yap<sup>2</sup>, Reyner L. Munarriz<sup>3</sup>, Pedro H. Zambrano<sup>4</sup>, Joseph T. Flynn<sup>5</sup>, Ilmay Bilge<sup>6</sup>, Maria Szczepanska<sup>7</sup>, Wai-Ming Lai<sup>8</sup>, Zenaida L. Antonio<sup>9</sup>, Ashima Gulati<sup>10</sup>, Nakysa Hooman<sup>11</sup>, Koen van Hoeck<sup>12</sup>, Lina M.S. Higueta<sup>13</sup>, Enrico Verrina<sup>14</sup>, Günter Klaus<sup>15</sup>, Michel Fischbach<sup>16</sup>, Mohammed A. Riyami<sup>17</sup>, Emilja Sahpazova<sup>18</sup>, Anja Sander<sup>19</sup>, Bradley A. Warady<sup>20</sup> and Franz Schaefer<sup>21</sup> for the International Pediatric Peritoneal Dialysis Network (IPPN) Registry<sup>22</sup>

- Icodextrin associated with increased risk of developing oligoanuria HR 2.38 (1.33-4.2) and lower residual urine output (p=0.043)
- Biocompatible fluid associated with greater residual urine output (p=0.028)






# PD Rx: Fill Volume

- Peritoneal membrane area is related to body size
- Use body surface area to calculate fill volume (as opposed to weight)
- Fill volume affects peritoneal membrane recruitment and diffusion capacity

↑ Volume = ↑ Clearance




# PD Rx: Fill Volume

## APD:

- Nocturnal fill volume:
  - >2 years: 1000-1200 mL/m<sup>2</sup>
  - < 2 years: 600-800 mL/m<sup>2</sup>
- Daytime Fill volume:
  - 50% of nocturnal fill volume

## CAPD:

- 600-800 mL/m<sup>2</sup> (day)
- 800-1000 mL/m<sup>2</sup> (night)



# Measuring IPP

Intra-peritoneal pressure maximum 18 cm H<sub>2</sub>O  
Normal 7-14 cm H<sub>2</sub>O

- Empty bladder
- Patient placed completely flat
- Connection made to peritoneal system
- Any fluid in abdominal cavity is drained and defined volume of PD fluid is instilled
- PD line is fixed vertically
- Zero level of column (on graduated scale) is set at center of abdominal cavity, on the medial axillary line
- Connection of line to patient is opened
- Level of column of dialysis fluid in the PD line is read with a scale graduated in cm after height of column stabilizes



**Fig. 1** The zero level of the column (*on the graduated scale*) is set at the centre of the abdominal cavity, i.e. medial axillary line.

$$\text{Mean IPP} = \frac{\text{IPP insp} + \text{IPP exp}}{2}$$




# PD Rx: Excess Volume

Intra-peritoneal pressure maximum 18 cm H<sub>2</sub>O  
Normal 7-14 cm H<sub>2</sub>O

Excess volume:

- Loss of UF
- Pain
- Risk of hernia
- Risk of hydrothorax
- Risk of breathing problems



# *PD Rx: Dwell Time*

## **Short exchanges**

- Clearance of small solutes (urea)
- Better ultrafiltration

## **Long exchanges**

- Clearance of higher molecular weight (creatinine and phosphate)
- Less ultrafiltration

***Dwell time should be determined by individual peritoneal membrane transport status***

# *PD Rx: # Exchanges*

## **APD**

- 5-10 exchanges overnight
- 9-12 hours
- Daytime dwell

## **CAPD**

- 3-5 exchanges/day
- 4-5 hour dwell time, with longer overnight dwell

# PD Rx cheat sheet

## Automated PD

### **Solution:**

1.5%, 2.5% or 4.25% Dianeal

### **Fill volume (nocturnal):**

< 2 years old = 600-800 mL/m<sup>2</sup>

> 2 years old = 1000-1200 mL/m<sup>2</sup>

### **Last fill (daytime):**

1/2 the nocturnal fill volume

### **#exchanges over #hours:**

5-10 exchanges overnight over 9-12 hrs

*Fill/Drain time:* 15 minutes

*Dwell time:* 40-60 minutes

## CAPD

### **Solution:**

1.5%, 2.5% or 4.25% Dianeal

### **Fill volume (daytime):**

600-800 mL/m<sup>2</sup>

### **Long overnight dwell(nocturnal):**

800-1000 mL/m<sup>2</sup>


### **# exchanges:**

3-5 exchanges/day with  
dwell time: 4 hours **AND**

1 nocturnal exchange with  
dwell time: ~9 hours

# Peritoneal Equilibration Test (PET)



- Test of peritoneal membrane transport
- 4 hour dwell, 1,100 mL/m<sup>2</sup> BSA, 2.5% Dextrose
- “Short” PET – 2 hours



# PET: *Transporter Type*

Category of peritoneal transport	D/P urea <sup>a</sup>	D/P creatinine <sup>a</sup>	D/D0 glucose <sup>a</sup>
High	0.91–0.94	0.77–0.88	0.12–0.21
High average	0.82–0.90	0.64–0.76	0.22–0.32
Low average	0.74–0.81	0.51–0.63	0.33–0.42
Low	0.54–0.73	0.37–0.50	0.43–0.55

<sup>a</sup>At a 4 h dwell of an exchange performed with 1,100 ml/m<sup>2</sup> BSA of a 2.5% dextrose solution



# PET: *Transporter Type*

Transporter Type	Characteristics	Prescription
<b>High</b>	<ul style="list-style-type: none"> <li>-Highly permeable membrane</li> <li>-Rapid solute clearance</li> <li>-Loss of osmotic gradient quickly (poor UF)</li> <li>-Higher protein loss (lower albumin)</li> </ul>	<ul style="list-style-type: none"> <li>-Shorter dwell times</li> <li>-NIPD, or APD with icodextrin daytime fill</li> </ul>
<b>High Average</b>	<ul style="list-style-type: none"> <li>-Efficient membrane</li> <li>-Good solute clearance</li> <li>-Good UF</li> </ul>	<ul style="list-style-type: none"> <li>-Any dialysis regimen</li> </ul>
<b>Low Average</b>	<ul style="list-style-type: none"> <li>-Less efficient membrane</li> <li>-Slower solute clearance</li> <li>-Good UF</li> </ul>	<ul style="list-style-type: none"> <li>-Any dialysis regimen, but with fewer cycles</li> </ul>
<b>Low</b>	<ul style="list-style-type: none"> <li>-Low membrane permeability</li> <li>-Slow solute clearance</li> <li>-Very good UF</li> <li>-Lower protein loss (higher albumin)</li> </ul>	<ul style="list-style-type: none"> <li>-Larger fill volumes</li> <li>-Longer duration of dwell with less cycles</li> <li>-CAPD or CCPD</li> </ul>

# *PD Rx: Modeled Approach*

## **Kinetic Modeling Software Based Programs**

- PD-Adequest 2.0 (Baxter)
  - Validated in children
- Patient Online (Fresenius)



# *PD Rx: Adjustment*

## **Inadequate Clearance**

- Introduce daytime dwell
- Increase fill volume
- Lengthen exchange time
- Increase number of exchanges
- Increase solution tonicity

## **Inadequate Ultrafiltration**

- Increase solution tonicity
- Icodextrin
- Shorten exchange time

# *PD Adequacy*

Delivered dose of dialysis is “adequate”:

- Optimal growth
- Blood pressure control
- Optimal nutritional status
- Avoidance of hypovolemia and sodium depletion
- Adequate psychomotor development

# *Adequacy: Measures of Clearance*

- Solute Clearance Measures:
  - Weekly  $Kt/V_{\text{urea}}$
  - Weekly Creatinine Clearance
- Current guidelines and consensus statements favor use of  $Kt/V_{\text{urea}}$  as the 'standard' measure to follow

# $Kt/V_{\text{urea}}$

- “K” is representative of CLEARANCE of UREA
  - Kd = clearance of dialysis delivered
  - Kr = clearance of ‘residual’ renal function
- “t” is the time over which dialysis is delivered
  - In PD calculations, “t” is normally considered 24 hours/day (calculation is based on full day of dialysate/urine output, then scaled to 1 week)
- “V”<sub>urea</sub> is the volume of distribution for Urea in the patient, which is the patient’s TBW

**Total  $Kt/V_{\text{urea}}$  = dialysis + renal clearance**

**Weekly Peritoneal Dialysis  $Kt/V$**

$$\frac{24 \text{ Hr D/P urea} \times 24\text{-hr drained volume} \times 7}{V}$$

**Weekly Renal  $Kt/V$**

$$\frac{\text{mL/min Urea clearance} \times 1440 \text{ min/day} \times 7}{1000 \text{ mL} \times V}$$

**Daily Renal Urea Clearance**

$$\frac{\text{Volume of 24-hr urine in mL} \times \text{Urine Urea Nitrogen Conc.}}{1440 \text{ min/day} \times \text{BUN Concentration}}$$

# *Total Body Water Calculation*

Males:  $TBW = 0.010$

$$\begin{aligned} & \bullet (\text{height} \cdot \text{weight})^{0.68} \\ & \quad - 0.37 \cdot \text{weight} \end{aligned}$$

Females:  $TBW = 0.14$

$$\begin{aligned} & \bullet (\text{height} \cdot \text{weight})^{0.64} \\ & \quad - 0.35 \cdot \text{weight} \end{aligned}$$



**Table 18. Female Total Body Water (L) Nomograms**


		Height (cm)																
		50	54	58	62	66	70	74	78	82	86	90	94	98	102	106	110	114
Weight (kg)	2	2.0	2.1	2.2	2.4													
	3	2.4	2.6	2.8	2.9													
	4	2.8	3.0	3.2	3.4	3.6												
	5	3.1	3.3	3.5	3.8	4.0												
	6	3.3	3.6	3.8	4.1	4.3	4.6	4.8										
	7	3.5	3.8	4.1	4.4	4.8	4.9	5.2	5.5	5.7								
	8	3.7	4.0	4.3	4.6	4.9	5.2	5.5	5.8	6.1	6.4	6.6						
	9				4.9	5.2	5.5	5.8	6.1	6.4	6.7	7.0	7.3	7.6				
	10				5.1	5.4	5.8	6.1	6.4	6.8	7.1	7.4	7.7	8.0	8.3	8.6		
	11				5.3	5.6	6.0	6.4	6.7	7.1	7.4	7.7	8.1	8.4	8.7	9.0	9.3	9.6
	12				5.4	5.8	6.2	6.6	7.0	7.3	7.7	8.0	8.4	8.7	9.1	9.4	9.7	10.0
	13								7.2	7.6	8.0	8.3	8.7	9.1	9.4	9.8	10.1	10.4
	14								7.4	7.8	8.2	8.6	9.0	9.4	9.7	10.1	10.5	10.8
	15								7.6	8.0	8.5	8.9	9.3	9.7	10.0	10.4	10.8	11.2
	16								7.8	8.3	8.7	9.1	9.5	9.9	10.3	10.7	11.1	11.5
	17											9.3	9.8	10.2	10.6	11.0	11.4	11.8
	18											9.6	10.0	10.5	10.9	11.3	11.7	12.2
	19											9.8	10.2	10.7	11.1	11.6	12.0	12.5
	20											10.0	10.4	10.9	11.4	11.8	12.3	12.7

**Table 18 (cont'd). Female Total Body Water (L) Nomograms**

		Height (cm)																						
		106	110	114	118	122	126	130	134	138	142	146	150	154	158	162	166	170	174	178	182	186	190	
Weight (kg)	20	11.8	12.3	12.7	13.2	13.6	14.0	14.5	14.9	15.3	15.7	16.1	16.5											
	22	12.3	12.8	13.3	13.7	14.2	14.7	15.1	15.6	16.0	16.4	16.9	17.3											
	24	12.8	13.3	13.8	14.3	14.8	15.2	15.7	16.2	16.7	17.1	17.6	18.0	18.5	18.9	19.4								
	26	13.2	13.7	14.2	14.8	15.3	15.8	16.3	16.8	17.3	17.8	18.3	18.7	19.2	19.7	20.1								
	28	13.6	14.1	14.7	15.2	15.8	16.3	16.8	17.3	17.9	18.4	18.9	19.4	19.9	20.4	20.9	21.3	21.8						
	30	13.9	14.5	15.1	15.7	16.2	16.8	17.3	17.9	18.4	18.9	19.5	20.0	20.5	21.0	21.5	22.0	22.5						
	32	14.3	14.9	15.5	16.1	16.6	17.2	17.8	18.4	18.9	19.5	20.0	20.6	21.1	21.7	22.2	22.7	23.2	23.7	24.3				
	34	14.6	15.2	15.8	16.4	17.0	17.7	18.2	18.8	19.4	20.0	20.6	21.1	21.7	22.3	22.8	23.4	23.9	24.4	25.0				
	36	14.8	15.5	16.2	16.8	17.4	18.1	18.7	19.3	19.9	20.5	21.1	21.7	22.3	22.8	23.4	24.0	24.5	25.1	25.6	26.2	26.7		
	38	15.1	15.8	16.5	17.1	17.8	18.4	19.1	19.7	20.3	21.0	21.6	22.2	22.8	23.4	24.0	24.6	25.1	25.7	26.3	26.9	27.4		
	40			16.8	17.4	18.1	18.8	19.5	20.1	20.7	21.4	22.0	22.7	23.3	23.9	24.5	25.1	25.7	26.3	26.9	27.5	28.1	28.6	
	42			17.0	17.7	18.4	19.1	19.8	20.5	21.1	21.8	22.5	23.1	23.8	24.4	25.0	25.7	26.3	26.9	27.5	28.1	28.7	29.3	
	44			17.3	18.0	18.7	19.5	20.2	20.9	21.5	22.2	22.9	23.6	24.2	24.9	25.5	26.2	26.8	27.4	28.1	28.7	29.3	29.9	
	46			17.5	18.3	19.0	19.8	20.5	21.2	21.9	22.6	23.3	24.0	24.7	25.3	26.0	26.7	27.3	28.0	28.6	29.3	29.9	30.5	
	48			17.8	18.5	19.3	20.0	20.8	21.5	22.3	23.0	23.7	24.4	25.1	25.8	26.5	27.2	27.8	28.5	29.2	29.8	30.5	31.1	
	50			18.0	18.8	19.6	20.3	21.1	21.8	22.6	23.3	24.1	24.8	25.5	26.2	26.9	27.6	28.3	29.0	29.7	30.4	31.0	31.7	
	52						20.6	21.4	22.1	22.9	23.7	24.4	25.2	25.9	26.6	27.4	28.1	28.8	29.5	30.2	30.9	31.6	32.2	
	54						20.8	21.6	22.4	23.2	24.0	24.8	25.5	26.3	27.0	27.8	28.5	29.2	29.9	30.7	31.4	32.1	32.8	
	56						21.1	21.9	22.7	23.5	24.3	25.1	25.9	26.6	27.4	28.2	28.9	29.7	30.4	31.1	31.9	32.6	33.3	
	58						21.3	22.1	23.0	23.8	24.6	25.4	26.2	27.0	27.8	28.5	29.3	30.1	30.8	31.6	32.3	33.1	33.8	
	60						21.5	22.4	23.2	24.1	24.9	25.7	26.5	27.3	28.1	28.9	29.7	30.5	31.3	32.0	32.8	33.5	34.3	
	62						21.7	22.6	23.4	24.3	25.2	26.0	26.8	27.7	28.5	29.3	30.1	30.9	31.7	32.4	33.2	34.0	34.8	
	64						21.9	22.8	23.7	24.6	25.4	26.3	27.1	28.0	28.8	29.6	30.4	31.3	32.1	32.9	33.6	34.4	35.2	
	66						24.8	25.7	26.5	27.4	28.3	29.1	30.0	30.8	31.6	32.4	33.2	34.1	34.9	35.7				
	68						25.0	25.9	26.8	27.7	28.6	29.4	30.3	31.1	32.0	32.8	33.6	34.5	35.3	36.1				
	70						25.2	26.1	27.0	27.9	28.8	29.7	30.6	31.5	32.3	33.2	34.0	34.9	35.7	36.5				
	72							25.4	26.4	27.3	28.2	29.1	30.0	30.9	31.8	32.7	33.5	34.4	35.2	36.1	36.9			
	74							25.6	26.6	27.5	28.4	29.4	30.3	31.2	32.1	33.0	33.9	34.7	35.6	36.5	37.3			
	76							25.8	26.8	27.7	28.7	29.6	30.6	31.5	32.4	33.3	34.2	35.1	36.0	36.8	37.7			
	78							26.0	27.0	27.9	28.9	29.9	30.8	31.7	32.7	33.6	34.5	35.4	36.3	37.2	38.1			
	80							26.2	27.2	28.1	29.1	30.1	31.1	32.0	33.0	33.9	34.8	35.7	36.7	37.6	38.5			



# KDOQI



The minimal “delivered” dose of total (peritoneal and kidney) small-solute clearance should be a  $Kt/V_{\text{urea}}$  of at least 1.8/week

# *Residual Kidney Function*

- Should be measured when UOP > 100 mL/day
- Defined as urine  $Kt/V_{\text{urea}} > 0.1/\text{week}$
- If the patient has RKF and residual kidney clearance is being considered as part of the patient's total weekly solute clearance goal, a 24 hour urine collection for urine volume and solute clearance determinations should be obtained at a minimum of every 3 months

# *Residual Kidney Function*

- May have a significant impact on patient outcome
- Efforts should be made to preserve RKF
  - Minimize nephrotoxic insults
  - Promptly treat UTIs
  - Diuretics to maximize salt and water excretion
  - Use of ACE/ARBs

# *Ultrafiltration Adequacy: Euvolemia*

## **Causes of Fluid Overload**

- Inappropriate solution selection
- Inappropriate prescription for membrane transport status
- Non-adherence to PD or diet
- Peritoneal membrane dysfunction
- Loss of residual renal function
- Poor blood glucose control

# *Management*

- The pediatric patient's clinical status should be reviewed at least monthly, and delivery of prescribed solute clearance should render the patient free of signs and symptoms of uremia
- Measure Kt/V one month after starting dialysis, when clinically needed and *at least* every 6 months
- PD effluent UF should be reviewed every month

# Summary

- PD prescription must be individualized and optimized, and continually re-assessed
- While recommended minimal “delivered” dose of solute clearance should be a  $Kt/V_{\text{urea}}$  1.8/week, adequacy is also determined by clinical outcomes of the patient
  - BP control, fluid management, growth, nutrition, bone disease, development

# Useful Resources

- Optimal Care of the Infant, Child and Adolescent on Dialysis: 2014 Update. *Am J Kidney Dis* 2014; 64(1):128-142
- Care of the Pediatric Patient on Chronic Dialysis. *Adv Chronic Kidney Dis* 2017; 24(6): 388-397
- Pediatric Dialysis, 2<sup>nd</sup> Edition. Warady, Schaefer, Alexander.
  - Chapter 11 Technical Aspects of Prescription of Peritoneal Dialysis in Children, p 169-203
- Handbook of Dialysis, 5<sup>th</sup> Edition. Daugirdas, Blake and Ing.
  - Chapter 25 Adequacy of Peritoneal Dialysis p464-482
  - Chapter 26 Volume Status and Fluid Overload in Peritoneal Dialysis p483-489
  - Chapter 37 Dialysis in Infants and Children p693-712
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates. Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access. *Am J Kidney Dis* 2006; 28(suppl 1): S1

# Peritoneal Dialysis Simulator

www.Openpediatrics.org

Harvard University

**A** YOUR PROGRESS  
Prescription  
Fill Volume  
Initial fill volumes are typically 5-10 mL/kg, with gradual increases up to 20 to 25 mL/kg in smaller infants, and 30-45 mL/kg in older children. In this simulator, start your fill volumes at 5 mL/kg and increase your fill volumes to promote increased clearance as needed.  
The volume of each fill limits the amount of clearance that one can achieve, as molecules can only move down a concentration gradient. Thus, the volume of dialysate instilled in a 24-hour period is the total maximum clearance achieved, assuming 100% efficacy.  
With shorter cycles, one never reaches equilibrium between blood and dialysate, and thus the clearance may be less than the volume of dialysate.  
Steps To Advance  
 1. Select 5 mL/kg from the Fill Volume dropdown.

**B** YOUR PROGRESS  
Tactic 6  
Examine and evaluate your patient by completing the actions below:  
 1. Assess the Patient  
 2. Monitor Vital Signs  
 3. Check Fluid Balance  
 4. Check Effluent  
 5. Check Lab Results  
Select a Condition...  
Continue  
Results - Day 1  
Cycles 4  
PD Input 200 mL  
PD Output 220 mL  
PD Balance -20 mL  
Effluent  
Click to Enlarge  
Patient Info  
View Case History  
DIAGNOSIS: None  
NAME: Ryan WEIGHT: 2.7 kg  
AGE: 2 weeks LOCATION: NICU

**C** YOUR PROGRESS  
Your Patient Chart  
Patient Information  
History  
Helen, a previously healthy 7-year-old girl, presented to the emergency department with several days of high fevers, pallor and malaise. On presentation, she was tachycardic and hypotensive, and had a prolonged capillary refill time.  
Helen was admitted to the hospital where she was resuscitated with multiple boluses of crystalloid fluid. She also received a blood transfusion. Following resuscitation, she became edematous but required vasopressors for low blood pressure, which are now weaning off.  
In the last 24 hours, she has only made 5 mL of urine. Diuretics were administered without any improvement in urine output. A peritoneal dialysis catheter was inserted at the bedside in aseptic manner. A KUB shows the catheter in good position.  
PATIENT NAME: Helen  
PATIENT AGE: 7 years  
PATIENT WEIGHT: 23 kg  
LOCATION: PICU  
Back to Menu  
Begin Simulation

**D** YOUR PROGRESS  
Congratulations! Your final score is 90%.  
To view a scoring breakdown for each task, click View Details below.  
Scoring Summary  
 Task 1: Initial Setup YOUR SCORE: 100% View Details  
 Task 2: Inadequate Drain Bag Height YOUR SCORE: 100% View Details  
 Task 3: Poor Ultrafiltration YOUR SCORE: 100% View Details  
 Task 4: Dehydration YOUR SCORE: 100% View Details  
 Task 5: Hyponatremia YOUR SCORE: 58% View Details  
 Task 6: Hypokalemia YOUR SCORE: 100% View Details  
Score 93% or better to receive the gold medal!  
View End-of-Case Feedback


Screenshots of the various components of the peritoneal dialysis simulator. (A) The knowledge guide. (B) The tactics. (C) The case studies. (D) Learner-controlled feedback.



???Questions???

Thank you!

# PD Rx: Modality



# Effect of PD


## PD fluid

Glucose (1380-4250 mg/dl)  
GDP  
Lactate-, bicarbonate (34-40 mmol/l)  
pH 5.5 – 7.4  
Electrolytes




## Systemic PD effects


- GDP-, AGE accumulation
- Inflammation (IL-6, complement)
- Insufficient toxin removal
- Fluid, salt overload



## Local PD effects



Healthy peritoneum



Membrane transformation


Uremia  
Peritonitis



Water, salts, toxins  
proteins, cytokines

# PD Rx: Dwell Time

**Accelerated Peritoneal Examination**  
**APEX time indicates optimal dwell time for UF**



# Physiology of Blood Purification: Dialysis & Apheresis

Jordan M. Symons, MD


University of Washington School of Medicine

Seattle Children's Hospital


# Outline

- Physical principles of mass transfer
- Hemodialysis and CRRT
  - Properties of dialyzers
  - Concepts that underlie the HD procedure
- Peritoneal Dialysis
  - Peritoneal membrane physiology
  - Concepts that underlie the PD procedure
- Apheresis – basic principles of blood separation

# Diffusion




# Convection






# Effect of Pore Size on Membrane Selectivity



# Intermittent Hemodialysis (IHD)



- Blood perfuses extracorporeal circuit
- Dialysate passes on opposite side of membrane
- High efficiency system
- Particle removal mostly by diffusion
- Fluid removal by ultrafiltration (hydrostatic pressure across dialyzer membrane)




# Hollow Fiber Dialyzers







# Dialysis/Hemofiltration Membranes



**Capillary**



**Cross Section**



**Blood Side**

# Permeability Surface Area Product: $K_0A$

- $K_0A$  is a property of the *dialyzer*
- Describes maximum ability of dialyzer to clear a given substance


$K_0A = \text{permeability } (K_0) * \text{surface area } (A)$

# Clearance ( $K_D$ )


- Clearance ( $K_D$ ) describes ability of a dialyzer to remove a substance from the blood
- Changes with the dialysis prescription

$$K_D = fx \{K_0A, Q_B, Q_D\}$$


# Blood Flow and $K_0A$ : Effect on Clearance



# Blood Flow and Molecular Weight: Effect on Clearance







## *Small Molecules*


- Diffuse easily
- Higher  $K_d$  at given  $Q_b$ ,  $Q_d$

## *Larger Molecules*

- Diffuse slowly
- Lower  $K_d$  at given  $Q_b$ ,  $Q_d$

# Ultrafiltration (UF)


- Removal of water due to effects of pressure
- Solutes removed by convection at the same time
- UF capability of a dialyzer described by the UF coefficient ( $K_{uf}$ ) – ml/h/mmHg




## Ultrafiltration

- Hydrostatic pressure across membrane
- More water removal with  $\uparrow$ pressure,  $\uparrow K_{uf}$

# Continuous Renal Replacement Therapy (CRRT)



- Extracorporeal circuit similar to IHD
- Runs continuously
- Particle removal may be by diffusion, convection or a combination
- Fluid removal by ultrafiltration
- Clearance can be approximated by the total effluent rate




## Convection

- Small and large molecules move equally
- Limit is cut-off size of membrane
- Significant solute loss over time in CRRT

# Peritoneal Dialysis (PD)

- Sterile dialysate introduced into peritoneal cavity through a catheter
- Dialysate exchanged at intervals
- Particle removal by diffusion
- Fluid removal by ultrafiltration (osmotic gradient using dextrose)



# HD and PD: Physiological Differences


## Hemodialysis

- Artificial membrane
- Higher blood flow
- Continuous dialysate flow
- Can use hydrostatic pressures for UF

## Peritoneal Dialysis

- Natural membrane
- Capillary blood flow in peritoneum
- “Stationary” dialysate in most forms of PD
- Different approach to UF is required

# PD Transport: A Complex Scheme





# The “Three Pore” Model of Peritoneal Transport

- Large pores (>20 nm diameter)
  - Few in number (<10%)
  - Can permit protein transport
- Small pores (4 – 6 nm diameter)
  - Majority (90%)
  - Transport most small molecules
- Ultra-small pores (aquaporins)
  - 1–2%; account for nearly half of water flow

# Peritoneal Transport: An Interaction of Three Separate Processes

- Diffusion
- Ultrafiltration
- Fluid absorption

# Diffusion in PD: Key Factors

- Concentration gradient of solute (D/P)
- Mass transfer area coefficient (MTAC)
  - Effective peritoneal surface area
    - Surface area + vascularity
  - Diffusive characteristics of membrane for solute in question (permeability)


# Ultrafiltration in PD: Key Factors

- Osmotic gradient
- Reflection coefficient
  - i.e., how well the osmotic particle stays in the dialysate (“1” would be perfect)
- UF coefficient
- Hydrostatic and oncotic pressure gradients


# Fluid Absorption in PD

- Direct lymphatic absorption of peritoneal fluid
- Tissue absorption of peritoneal fluid
- Limits ultrafiltration and mass transfer
  - Higher levels of peritoneal absorption reduce net ultrafiltration

# Schematic of Molecular Transport in PD




# Apheresis




- “*Apheresis*”: Greek, “To take away or separate”
- Blood perfuses extracorporeal circuit
- Blood components separated; selected component removed
- If large volume removed replacement is required
- Uses include therapeutic indications or for blood component harvest

# Components of Whole Blood



*Separation and removal of individual components may be required for therapeutic need*














# Apheresis Methods

## Filtration

- Blood separation across a membrane by *size*


## Centrifugation

- Blood component separation by *density*


Filtration			Centrifugation		
		Diameter ( $\mu\text{m}$ )			Density (specific gravity)
	Plasma		Plasma		(1.025-1.029)
	 Platelet	3	 Platelet		(1.040)
	 Red cell	7	 Lymphocyte		(1.070)
	 Lymphocyte	10	 Granulocyte		(1.087-1.092)
	 Granulocyte	13	 Red cell		(1.093-1.096)

Select

# Effect of Pore Size In Dialysis



# Membrane Apheresis Employs Larger Pores




- Larger pores will allow proteins to pass through
- Blood cells are restricted
- Membrane system can be used for plasmapheresis, not cytapheresis

# Apheresis by Centrifugation




- Spinning centrifuge separates blood components by density
- Specific component may be selected for removal by choosing appropriate layer
- Permits plasmapheresis and cytapheresis

# Apheresis by Centrifugation



# Fraction Removed from Plasma by Plasma Volume Replaced



- IgG: only 45% intravascular
- 1.5 vol removes ~35% of total body IgG
- Re-equilibration within ~2 days
- Repeated session QOD often needed

# Physiology of Blood Purification: Summary

- Basic concepts of *diffusion* and *convection* underlie all dialysis methods
  - **HD**: Diffusion + hydrostatic-pressure UF
  - **CRRT**: Diffusion and/or convection + hydrostatic-pressure UF
  - **PD**: Diffusion + osmotic-pressure UF
- Blood components separated by centrifugation or membrane in **apheresis**